版本:
中国

BRIEF-Amag submits supplemental NDA for makena auto-injector

April 17 Amag Pharmaceuticals Inc

* Amag submits supplemental new drug application to FDA for makena (hydroxyprogesterone caproate injection) auto-injector for subcutaneous use

* Anticipates a six-month FDA review timeline with potential for approval and launch in Q4 of 2017

* Amag Pharmaceuticals - if makena auto-injector is approved, Amag will request orange book listing of eligible antares patents, last of which expires in 2026 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐